Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2008 Jan 28;7(3):863–869. doi: 10.1111/j.1750-3639.1997.tb00889.x

Fas Ligand Expression in Glioblastoma Cell Lines and Primary Astrocytic Brain Tumors

Catherine Gratas 1, Yasuo Tohma 1, Erwin G Van Meir 3, Michael Klein 2, Mirna Tenan 3, Nobuaki Ishii 3, Osamu Tachibana 1, Paul Kleihues 1,2, Hiroko Ohgaki 1,✉
PMCID: PMC8098208  PMID: 9217971

Abstract

Fas/APO‐1 (CD95) is a cell surface receptor that mediates apoptosis when it reacts with Fas ligand (FasL) or Fas antibody. We previously reported that Fas expression is predominantly induced in perinecrotic glioma cells, suggesting that Fas induction is associated with apoptosis and necrosis formation, a histological hallmark of glioblastomas. In this study, we assessed the expression of FasL in 10 glioblastoma cell lines and in 14 astrocytic brain tumors (three low‐grade astrocytomas and 11 glioblastomas). Reverse transcriptase (RT)‐PCR revealed that all glioblastoma cell lines and primary astrocytic brain tumors express FasL. Immunohistochemically, FasL was predominantly expressed on the plasma membrane of glioma cells. These results suggest that FasL expression is common in human astrocytic brain tumors and may cause apoptosis of glioma cells if Fas expression is induced.

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

References

  • 1. Alderson MR, Tough TW, Davis Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH (1995) Fas ligand mediates activation‐induced cell death in human T lymphocytes. J Exp Med 181: 71–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Barker FG, Davis RL, Chang SM, Prados MD (1996) Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 77: 1161–1166. [DOI] [PubMed] [Google Scholar]
  • 3. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC (1995) A role for CD95 ligand in preventing graft rejection. Nature 377: 630–632. [DOI] [PubMed] [Google Scholar]
  • 4. Burger PC Scheithauer BW (1994) Tumors of the Central Nervous System. Armed Forces Institute of Pathology: Washington , DC . [Google Scholar]
  • 5. Cheng J, Liu C, Koopman WJ, Mountz JD (1995) Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol 154: 1239–1245. [PubMed] [Google Scholar]
  • 6. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fasmediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759–1762. [DOI] [PubMed] [Google Scholar]
  • 7. Chomczynski P, Sacchi N (1987) Single‐step method of RNA isolation by guanidium thiocyanate‐phenol‐chloroform extraction. Anal Biochem 162: 156–159. [DOI] [PubMed] [Google Scholar]
  • 8. Daumas Duport C, Scheithauer B, O'Fallon J, Kelly P (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62: 2152–2165. [DOI] [PubMed] [Google Scholar]
  • 9. Dowling P, Shang G, Raval S, Menonna J, Cook S, Husar W (1996) Involvement of the CD95 (APO‐1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 184: 1513–1518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J, Tada M, Van Meir EG, Estreicher A, Iggo RD (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963–3967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K, Muller C, Tschopp J (1996) Fas and Fas ligand in embryos and adult mice: ligand expression in several immune‐privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 133: 335–343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand‐induced apoptosis as a mechanism of immune privilege. Science 270: 1189–1192. [DOI] [PubMed] [Google Scholar]
  • 13. Hahne M, Renno T, Schroeter M, Irmler M, French L, Bornard T, MacDonald HR, Tschopp J (1996) Activated B cells express functional Fas ligand. Eur J Immunol 26: 721–724. [DOI] [PubMed] [Google Scholar]
  • 14. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J‐C, Tschopp J (1996) Melanoma cell expression of Fas(Apo‐1/CD95) ligand: implications for tumor immune escape. Science 274: 1363–1366. [DOI] [PubMed] [Google Scholar]
  • 15. Jain RK (1988) Determinants of tumor blood flow: a review. Cancer Res 48: 2641–2658. [PubMed] [Google Scholar]
  • 16. Kleihues P, Burger PC, Scheithauer BW (1993) Histological Typing of Tumours of the Central Nervous System. World Health Organization International Histological Classification of Tumours. 2nd edition, Springer Verlag: Berlin, Heidelberg . [Google Scholar]
  • 17. Kleihues P, Ohgaki H, Aguzzi A (1995) Neuroglia. In: Gliomas, Kettenmann H, Ransom BR (eds.), pp. 1044–1063, Oxford University Press: Oxford . [Google Scholar]
  • 18. Knipping E, Debatin KM, Strieker K, Heilig B, Eder A, Krammer PH (1995) Identification of soluble APO‐1 in supernatants of human B‐ and T‐cell lines and increased serum levels in B‐ and T‐cell leukemias. Blood 85: 1562–1569. [PubMed] [Google Scholar]
  • 19. Koji T, Kobayashi N, Nakanishi Y, Yoshii A (1994) Immunohistochemical localization of Fas antigen in paraffin sections with rabbit antibodies against human synthetic Fas peptides. Acta Histochem Cytochem 27: 459–463. [Google Scholar]
  • 20. Kordek R, Hironishi M, Liberski PP, Yanagihara R, Gajdusek DC (1996) Apoptosis in glial tumors as determined by in situ nonradioactive labeling of DNA breaks. Acta Neuropathol Berl 91: 112–116. [DOI] [PubMed] [Google Scholar]
  • 21. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P (1993) Constitutive and induced expression of APO‐1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69: 415–429. [PubMed] [Google Scholar]
  • 22. Loughran TP, Jr. (1993) Clonal diseases of large granular lymphocytes. Blood 82: 1–14. [PubMed] [Google Scholar]
  • 23. Nagata S, Golstein P (1995) The Fas death factor. Science 267: 1449–1456. [DOI] [PubMed] [Google Scholar]
  • 24. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F (1996) The Fas‐counterattack: Fas‐mediated T‐cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075–1082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845–848. [DOI] [PubMed] [Google Scholar]
  • 26. Plate KH, Risau W (1995) Angiogenesis in malignant gliomas. Glia 15: 339–347. [DOI] [PubMed] [Google Scholar]
  • 27. Sawamura Y, de Tribolet N (1990) Advances and technical standards in neurosurgery. In: Immunobiology of Brain Tumors, Symon L, Calliauw L, Cohadon F, Guidetti B, Loew F, Nomes H, Pasztor E, Pertuiset B, Pickard JD, Yasargil MG (eds.), pp. 3–64, Springer‐Verlag: Vienna, New York . [DOI] [PubMed] [Google Scholar]
  • 28. Schiffer D, Cavalla P, Migheli A, Chio A, Giordana MT, Marino S, Attanasio A (1995) Apoptosis and cell proliferation in human neuroepithelial tumors. Neurosci Lett 195: 81–84. [DOI] [PubMed] [Google Scholar]
  • 29. Shweiki D, Itin A, Softer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia‐iritiated angiogenesis. Nafure 359: 843–845. [DOI] [PubMed] [Google Scholar]
  • 30. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO‐1/Fas) ligand‐expressing tumor cells—A mechanism of immune evas on Nat Med 2: 1361–1366. [DOI] [PubMed] [Google Scholar]
  • 31. Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169–1178. [DOI] [PubMed] [Google Scholar]
  • 32. Tachibana O, Lampe K, Kleihues P, Ohgaki H (1996) Preferential expression of Fas/APO‐1 (CD95) and apoptotic cell death in perinecrotic cells of the glioblastoma multiforme. Acta Neuropathol 92: 431–434. [DOI] [PubMed] [Google Scholar]
  • 33. Tachibana C, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H (1995) Expression of Fas/APO‐1 during the progression of astrocytomas. Cancer Res 55: 5528–5530. [PubMed] [Google Scholar]
  • 34. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S (1994) Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 6: 1567–1574. [DOI] [PubMed] [Google Scholar]
  • 35. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK (1994) Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649–652. [PubMed] [Google Scholar]
  • 36. Watanabe‐Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S (1992) The cDNA structure, expression and chromosomal assignment of the mouse Fas antigen. J Immunol 148: 1274–1279. [PubMed] [Google Scholar]
  • 37. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A (1994) Anti‐Fas/APO‐1 antibody‐mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 94: 954–964. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES